PhRMA submission to the 2019 National Trade Estimate Report urges action to protect U.S. biopharmaceutical innovation
By Douglas Petersen | November 2, 2018
International trade is critical to delivering life-saving and life-enhancing medicines in the global economy, which is why PhRMA addresses several discriminatory foreign government practices in...
Read More
Here’s how America’s biopharmaceutical companies lead the way in development of innovative new medicines
By Andrew Powaleny | July 25, 2018
In today’s new era of medicine, America’s biopharmaceutical companies are conducting some of the most complex and difficult research in the world to develop innovative treatments for patients.
Read More
Event next week: Supporting the next generation of lifesaving medicines
By Andrew Powaleny | July 12, 2018
The remarkable scientific advancements in recent history are due, in part, to thoughtful public policies that promote innovation and discovery. These policies support the tireless efforts of more...
Read More
Celebrating U.S. innovation as USPTO issues the 10 millionth patent
By Nicole Longo | June 19, 2018
The U.S. patent system has supported innovation and discovery dating back to the founding of our nation and the signing of the U.S. Constitution, encouraging Americans to continue to search for...
Read More
Supreme Court decisions in two cases pave way for IPR reforms
By Nicole Longo | May 31, 2018
At the end of April, the Supreme Court decided two cases concerning the inter partes review (IPR) proceedings enacted as part of the 2011 America Invents Act (AIA). While distinct cases, together...
Read More
To continue to drive the innovation economy and exports, American biopharmaceutical sector depends on fair trade agreements
By Jay Taylor | May 10, 2018
May is World Trade Month, when we celebrate the many American companies exporting products around the world, and growing opportunities here in the U.S.
Read More
What is inter partes review and why does it matter?
By Nicole Longo | March 16, 2018
For more than three decades Hatch-Waxman (the Drug Price Competition and Patent Term Restoration Act of 1984) has encouraged innovation in biopharmaceutical development while at the same time...
Read More
Supporting opportunities for enhanced competition in the marketplace
By Andrew Powaleny | November 22, 2017
Promoting competition is an important focus for the biopharmaceutical industry. Since 1984, the Hatch-Waxman Act has fostered robust competition through the timely entry of generic medicines into...
Read More
Biopharma leads sustained economic growth driven by IP-intensive industries
By Tim McClung | September 26, 2017
While the biopharmaceutical industry is the global leader in generating innovative medicines and technologies, lesser known is the industry’s central role in sustaining economic growth. A recent...
Read More
Opportunities to build upon enhanced competition for medicines in the marketplace
By David Korn | July 27, 2017
Last week, I presented at the U.S Food and Drug Administration’s (FDA) public meeting on the Hatch-Waxman Amendments to discuss the balance between encouraging innovation in biopharmaceutical...
Read More
Medicare Monday (100)
340B Spotlight (37)
Cost & Consequence (0)
